Table 2.
Univariate analysis for DFS and OS
| Variable | No. of patients (%) | DFS |
OS |
||||
|---|---|---|---|---|---|---|---|
| 5-Yr DFS (%) | 95% CI | p-value | 5-Yr OS (%) | 95% CI | p-value | ||
| Age (yr) | |||||||
| ≤ 60 | 36 (40) | 56.9 | 40.2-73.6 | 0.076 | 62.7 | 46.4-79.0 | 0.049 |
| > 60 | 55 (60) | 49.1 | 35.4-62.8 | 54.2 | 40.5-67.9 | ||
| Sex | |||||||
| Female | 5 (6) | 80.0 | 44.9-115.1 | 0.396 | 75.0 | 32.5-117.5 | 0.260 |
| Male | 86 (94) | 50.3 | 39.3-61.3 | 55.0 | 44.0-66.0 | ||
| Subsite | |||||||
| PS | 73 (80) | 54.5 | 42.7-66.3 | 0.606 | 60.2 | 48.6-71.8 | 0.887 |
| PW/PC | 18 (20) | 42.9 | 19.2-66.6 | 46.2 | 21.5-70.9 | ||
| T stage | |||||||
| T1-2 | 34 (37) | 57.8 | 40.7-74.9 | 0.539 | 60.0 | 42.9-77.1 | 0.641 |
| T3-4 | 57 (63) | 48.8 | 35.3-62.3 | 56.2 | 42.7-69.7 | ||
| N stage | |||||||
| N0-1 | 26 (29) | 52.6 | 33.0-72.2 | 0.652 | 59.3 | 39.5-79.1 | 0.517 |
| N2-3 | 65 (71) | 51.9 | 39.2-64.6 | 56.6 | 44.1-69.1 | ||
| Treatment | |||||||
| SRT | 57 (63) | 52.7 | 39.4-66.0 | 0.991 | 56.6 | 43.5-69.7 | 0.713 |
| CRT | 34 (37) | 51.0 | 33.4-68.6 | 58.6 | 41.0-76.2 | ||
| RT | |||||||
| IMRT | 18 (20) | 35.7 | 12.2-59.2 | 0.116 | 53.6 | 27.1-80.0 | 0.873 |
| 3DCRT | 73 (80) | 56.3 | 44.5-68.1 | 57.9 | 46.3-69.5 | ||
DFS, disease-free survival; OS, overall survival; CI, confidence interval; PS, pyriform sinus; PW, pharyngeal wall; PC, postcricoid; SRT, surgery plus radiotherapy; CRT, chemoradiotherapy; RT, radiotherapy; IMRT, intensity modulated radiotherapy; 3DCRT, 3 dimensional conformal radiotherapy.